Literature DB >> 23257663

Intravitreal ranibizumab for acute central serous chorioretinopathy.

Moosang Kim1, Seung-Chan Lee, Seung-Jun Lee.   

Abstract

BACKGROUND/AIMS: To evaluate the effectiveness of intravitreal ranibizumab injection (IVRI) for acute central serous chorioretinopathy (CSC).
METHODS: Patients with symptomatic CSC of less than 3 months were prospectively recruited. Patients (n = 20/group) were randomly assigned to IVRI (0.5 mg/0.05 ml) or observation and followed for 6 months. logMAR best-corrected visual acuity (BCVA), fluorescein angiography, indocyanine angiography, and central foveal thickness (CFT) were assessed at baseline and at regular follow-ups.
RESULTS: All patients had increased BCVA, decreased CFT, and resolution of the neurosensory detachment. Complete resolution of neurosensory retinal detachment required more time in the observation group (13.0 ± 3.1 vs. 4.2 ± 0.9 weeks; p < 0.001). Mean BCVA and mean CFT improved significantly in both groups, but the changes were not significantly different between groups at 6 months.
CONCLUSIONS: IVRI for acute CSC might hasten resolution of neurosensory detachment compared to observation alone. At 6 months, BCVA and CFT did not differ between IVRI and observation groups. Further studies are required to determine the long-term benefits of IVRI.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257663     DOI: 10.1159/000345495

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  9 in total

Review 1.  Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.

Authors:  H Q Lu; E Q Wang; T Zhang; Y X Chen
Journal:  Eye (Lond)       Date:  2015-10-30       Impact factor: 3.775

2.  Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.

Authors:  Yang Jae Kim; Si Yeol Kim; Seungmin Ha; Daruchi Moon; San Seong; Oh Woong Kwon; Han Sang Park
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

3.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

Review 4.  Interventions for central serous chorioretinopathy: a network meta-analysis.

Authors:  Mahsa Salehi; Adam S Wenick; Hua Andrew Law; Jennifer R Evans; Peter Gehlbach
Journal:  Cochrane Database Syst Rev       Date:  2015-12-22

5.  Clinical application of optical coherence tomography in combination with functional diagnostics: advantages and limitations for diagnosis and assessment of therapy outcome in central serous chorioretinopathy.

Authors:  Joshua A Schliesser; Gary Gallimore; Nancy Kunjukunju; Nelson R Sabates; Peter Koulen; Felix N Sabates
Journal:  Clin Ophthalmol       Date:  2014-11-21

6.  Pituitary Apoplexy After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitor: A Novel Complication.

Authors:  Rebecca A Kasl; Heather M Kistka; Justin H Turner; Jessica K Devin; Lola B Chambless
Journal:  J Neurol Surg Rep       Date:  2015-08-24

7.  The Effect of Intravitreal Bevacizumab on Central Serous Chorioretinopathy.

Authors:  Alireza Maleki; Zahra Nezamdust; Amirmasoud Salari; Seyed Sajad Ahmadi; Hamideh Sabbaghi; Omid Bagherzadeh; Alireza Ataollahi; Mehdi Yaseri
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

8.  577 nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study.

Authors:  He Long; Maoxiong Liu; Qinghua Hu; Xin Li
Journal:  BMC Ophthalmol       Date:  2022-03-05       Impact factor: 2.209

9.  An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab: a case report.

Authors:  Michael Karampelas; Vasileios Soumplis; Dimitrios Karagiannis; Efstratios Parikakis; Andrew R Webster
Journal:  BMC Res Notes       Date:  2013-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.